Targeting Aggregated α-synuclein by ABL301: First-In-Class & Best-in-Class BBB Penetrating Bispecific Antibody

abl301-1.jpg

Blood Brain Barrier (BBB) & Benefit of BBB Shuttle Platform Development

alb301-2.jpg

BsAb with BBB Shuttle Penetrates Brains Better than Mono IgG In Vivo and Shows Better Efficacy.

Screenshot 2018-12-18 09.38.18.png

Competitive Advantages of ABL301

Screenshot 2018-12-18 11.52.01.png